COMPANY
Athos Therapeutics
Funding and NIH signals
- SEC Form D raise Raised $10.28M in debt securities (Form D filed May 15, 2026). SEC Form D 0001885079-26-000001 (May 15, 2026)
Evidence (1 event)
- May 15, 2026 · SEC Form D 0001885079-26-000001
Name of Issuer: Athos Therapeutics, Inc.; CIK: 1885079; Address: Torrance, CA; Submission type: D; Filing date: 2026-05-15; Industry Group: Pharmaceuticals; Date of First Sale: 2026-04-17; Types of Securities Offered: Debt, Security to be acquired; Business combination transaction: false; Total Offering Amount: 20000000; Total Amount Sold: 10282887; Federal exemptions: 06b
- May 15, 2026 · SEC Form D 0001885079-26-000001
Timeline
- Trial start Phase 2: Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC) source ↗
- Trial start Phase 1: Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATH-063 in Healthy Subjects source ↗
Upcoming milestones
- Dec 14, 2028 (ESTIMATED) · Phase 2 · Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC) · NCT07513181
Clinical trials (lead sponsor) 2
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07513181 | Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC) | Phase 2 | Recruiting | Apr 30, 2026 | Dec 14, 2028 (estimated) |
| NCT05807971 | Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATH-063 in Healthy Subjects | Phase 1 | Completed | Apr 6, 2023 | Feb 8, 2024 (actual) |